Interchangeability without switching studies: FDA explains why a new Lucentis biosimilar may be a game-changer

Of the nearly 40 biosimilars approved to date by the FDA, only three have won the coveted interchangeability designation so far, meaning that like small-molecule generic drugs, they can be  substituted at the pharmacy counter without the intervention of the prescriber.

Interchangeable biosimilars have been limited so far, as the…